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Abstract
Background Many adult congenital heart disease
(ACHD) patients are at risk of sudden cardiac death
(SCD). An implantable cardioverter-defibrillator (ICD)
may prevent SCD, but the evidence for primary pre-
vention indications is still unsatisfactory.
Study Design PREVENTION-ACHD is a prospective
study with which we aim to prospectively validate
a new risk score model for primary prevention of SCD
in ACHD patients, as well as the currently existing
guideline recommendations. Patients are screened us-
ing a novel risk score to predict SCD as well as current
ICD indications according to an international Con-
sensus Statement. Patients are followed up for two
years. The primary endpoint is the occurrence of SCD
and sustained ventricular arrhythmias. The Study was
registered at ClinicalTrials.gov (NCT03957824).
Electronic supplementary material The online version of
this article (https://doi.org/10.1007/s12471-019-1297-3)
contains supplementary material, which is available to
authorized users.
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Conclusion PREVENTION-ACHD is the first prospec-
tive study on SCD in ACHD patients. In the light of
What’s new?
 A novel risk score model presented here aims to
accurately predict SCD in several high-risk con-
genital heart defects.
 This risk score model is based on seven risk fac-
tors, identified from the largest study on SCD in
ACHD patients to date.
 The risk score model was internally validated, as
well as externally validated in an independent
cohort.
 PREVENTION-ACHD aims to validate the risk
score model in a prospective setting.
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a growing and aging population of patients with more
severe congenital heart defects, more robust clinical
evidence on primary prevention of SCD is urgently
needed.
Keywords Risk score · Risk stratification · Ventricular
tachycardia · Ventricular fibrillation · Primary
prevention
Introduction
Adult congenital heart disease (ACHD) patients face
the risk of a myriad of complications late after sur-
gical repair. Of these, sudden cardiac death (SCD) is
perhaps the most devastating; it accounts for up to
25% of all deaths in this young population [1–4]. As
a result of a higher birth prevalence of children with
congenital heart defects and improved screening, sur-
gical andmedical techniques, the population of ACHD
patients is growing rapidly [5, 6]. Moreover, the risk
of SCD may rise with longer post-operative follow-up,
as the number of risk factors accumulate, e.g. slowly
worsening ejection fraction and heart failure, as well
as atrial arrhythmias. Considering these aspects, the
overall incidence of SCD in ACHD patients can be ex-
pected to increase, and its prevention may prove to be
one of the next big challenges in the field of congenital
heart disease.
The implantable cardioverter-defibrillator (ICD)
was developed to prevent SCD resulting from ven-
tricular tachyarrhythmias, which are responsible for
approximately 80% of all SCDs in ACHD patients
[1]. It is a well-established therapy in patients with
ischaemic and non-ischaemic cardiomyopathy, for
whom ICD implantation for primary prevention is
supported by clearly defined guideline recommen-
dations [7–9]. However, extrapolation of guideline
recommendations for patients with acquired heart
disease may not be optimal for ACHD patients. Nev-
ertheless, guidelines for patients with acquired heart
disease have generally been used for risk stratifica-
tion for SCD in ACHD patients, because of a lack of
superior alternatives.
An assessment of the risk of SCD specifically for
ACHD patients is vital; the majority of ACHD patients
have a low risk of SCD, but some patients, particu-
larly those with more severe congenital lesions, are at
high risk. The implantation of an ICD in ACHD pa-
tients does result in a high rate of appropriate ICD
interventions, but data on the fate of those in whom
an ICD is not implanted is lacking [10]. Moreover,
ICD-related complications and inappropriate shocks
are abundant in ACHD patients who receive an ICD
[10]. This makes under- as well as over-implantation
a tremendous problem, but physicians are currently
not supported in the decision for or against ICD im-
plantation by robust clinical evidence.
Currently there are three documents that list rec-
ommendations for primary prevention ICD implanta-
tion in ACHD patients: the PACES/HRS Expert Con-
sensus Statement on the Recognition and Manage-
ment of Arrhythmias in Adult Congenital Heart Dis-
ease, the 2015 European Society of Cardiology (ESC)
Guidelines for the management of patients with ven-
tricular arrhythmias and the prevention of sudden
cardiac death, and the 2018 position paper of the Eu-
ropean Heart Rhythm Association (EHRA), Associa-
tion for European Paediatric and Congenital Cardiol-
ogy (AEPC), and the ESC Working Group on Grown-
up Congenital heart disease [9, 11, 12]. All three doc-
uments list essentially the same indications for ICD
implantation, such as systemic left ventricular ejec-
tion fraction ≤35% accompanied by New York Heart
Association (NYHA) class II or III heart failure symp-
toms. However, when these indications were applied
to a cohort of ACHD patients who died of SCD com-
pared to living matched controls, only a minority of
SCD cases was correctly identified, and a poor dis-
criminative ability between cases and controls was
found [13]. Therefore, a more accurate risk stratifi-
cation method for SCD is urgently needed to prevent
more deaths from occurring in the rapidly growing
population of adults with congenital heart disease.
In this study, we use a new risk stratification model,
which is based on risk factors in ACHD patients who
died of SCD, compared with living controls. The val-
idation of prognostic risk prediction models is highly
important [14, 15], particularly in this case, because
the models assessed here predict preventable death in
a group of young adults who are underrepresented in
international guidelines. We aim to test a novel risk
score that aims to accurately predict SCD in ACHD,
as well as the current ICD indications in the interna-
tional Consensus Statement on arrhythmias in ACHD
and evaluate the risk of SCD at follow-up [11].
Methods
Risk score model
We developed a risk score model with which we aim
to predict the annual risk of SCD or life-threaten-
ing arrhythmias in different types of congenital heart
defects (CHD). This risk score model was based on
a retrospective multicentre case-controlled study that
evaluated risk factors for SCD in ACHD patients. In
that study SCD cases were matched to living controls
by age, gender, diagnosis, type of surgical interven-
tion, date of surgical repair and treating medical cen-
tre [1].
To identify clinical variables associated with SCD,
univariable and stepwise backward multivariable con-
ditional logistic regression models were used. A de-
tailed description of the identification of the risk fac-
tors is described elsewhere [1], and in the online sup-
plementary material. The stability of the variable se-
lection procedure was evaluated with 1000 bootstrap
analyses. Variables selected at least 400 times were
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Fig. 1 The risk score
based on clinical risk fac-
tors represents the an-
nual risk of sudden cardiac
death. For each of the fol-
lowing seven risk factors
one point is attributed to the
model: 1 Coronary artery
disease, 2 Heart failure
symptoms (New York Heart
Association class II/III),
3 Supraventricular tachy-
cardia, 4 Impaired systemic
ventricular function (ejec-
tion fraction <40%), 5 Im-
paired subpulmonary ven-
tricular function (ejection
fraction <40%), 6 QRS du-
ration >120ms, 7 QT dis-
persion >70ms (ASD atrial
septal defect, SCD sudden
cardiac death, TGA trans-
position of the great ar-
teries, *Seven risk factors
not possible for Fontan pa-
tients, as these patients do
not have a subpulmonary
ventricle)
included in the final model. For all logistic regres-
sion models, odds ratios (OR) with 95% confidence
intervals were calculated. To determine the risk of
SCD, we developed a point-based risk scoring sys-
tem. Points were attributed to each variable in the
risk score model depending on the log odds ratio or
B-coefficient, which was derived from the multivari-
able analysis. The resulting risk score model consists
of seven risk factors for SCD, for each of which one
point is attributed to the model. This model was used
to assess the absolute annual risk of SCD by multiply-
ing the hazard ratio associated with one point in the
risk score by the number of points and the a-priori
risk of SCD for each CHD lesion (Fig. 1). The annual
incidence of SCD per congenital defect was derived
from the Concor registry [16]. The lesions with the
highest risk of SCD are included in the final model.
The performance of the risk score model was evalu-
ated using the area under the receiver operating char-
acteristics (AUROC) curve. We internally validated the
performance of our model by a second bootstrapping,
which included the variable selection bootstrapping
procedure. In addition to the internal validation, an
independent prospective registry cohort from La Paz
University Hospital, Madrid, Spain was used to exter-
nally validate the risk score model. From this cohort,
which includes 3311 adults with CHD from December
1989 to December 2013, all SCD cases were included
[17].
The clinical parameters included in the risk score
are identifiable through routine follow-up examina-
tions, such as the electrocardiogram and echocardio-
gram. Therefore it may especially be suitable for ap-
plication during outpatient clinic visits. However, not
all congenital heart defects are incorporated into this
risk score, predominantly because patients with other
defects have such a low a-priori risk of SCD that their
risk score cannot be calculated, or the congenital de-
fect is too uncommon to provide an accurate risk pre-
diction.
In addition to validating this risk score in a prospec-
tive setting, the Consensus Statement indications will
Screening of all adults with CHD at outpaent clinic using:
1. Risk score model
2. Consensus statement indicaons
Low-risk paents
SCD risk <3% (risk score)
and 
no ICD indicaon (consensus)
High-risk paents
SCD risk ≥3% (risk score)
and/or
ICD indicaon (consensus)
Sudden cardiac death or sustained ventricular arrhythmia
Hospital records aer two years of follow-up
Fig. 2 Flow chart of patient selection and follow-up (CHD con-
genital heart disease, ICD implantable cardioverter-defibrillator,
SCD sudden cardiac death). (Consensus: PACES/HRS Expert
Consensus Statement on the Recognition and Management
of Arrhythmias in Adult Congenital Heart Disease [11])
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Table 1 Primary prevention ICD indications according to the PACES/HRS Expert Consensus Statement on arrhythmia in
ACHD [11]
Class I
ICD therapy is indicated in adults with CHD and a systemic left ventricular ejection fraction ≤35%, biventricular physiology, and New York Heart Association
(NYHA) class II or III symptoms (Level of evidence: B)
Class IIa
ICD therapy is reasonable in selected adults with tetralogy of Fallot and multiple risk factors for sudden cardiac death, such as left ventricular systolic or dias-
tolic dysfunction, nonsustained ventricular tachycardia, QRS duration ≥180ms, extensive right ventricular scarring, or inducible sustained ventricular tachycar-
dia at electrophysiology study (Level of evidence: B)
Class IIb
1. ICD therapy may be reasonable in adults with a single or systemic right ventricular ejection fraction <35%, particularly in the presence of additional risk
factors such as complex ventricular arrhythmias, unexplained syncope, NYHA functional class II or III symptoms, QRS duration ≥140ms, or severe systemic AV
valve regurgitation (Level of evidence: C)
2. ICD therapy may be considered in adults with CHD and a systemic ventricular ejection fraction <35% in the absence of overt symptoms (NYHA class I) or
other known risk factors (Level of evidence of: C)
3. ICD therapy may be considered in adults with CHD and syncope of unknown origin with haemodynamically significant sustained ventricular tachycardia or
fibrillation inducible at electrophysiologic study (Level of evidence: B)
4. ICD therapy may be considered for nonhospitalised adults with CHD awaiting heart transplantation (Level of evidence: C)
5. ICD therapy may be considered for adults with syncope and moderate or complex CHD in whom there is a high clinical suspicion of ventricular arrhythmia
and in whom thorough invasive and noninvasive investigations have failed to define a cause (Level of evidence: C)
ICD implantable cardioverter-defibrillator, CHD congenital heart disease, ACHD adult congenital heart disease
also be verified in this study for their accuracy in
predicting SCD events and appropriate ICD interven-
tions.
Study design
This is a single centre, prospective, observational
study. Patients with an outpatient clinic appointment
at the Academic Medical Center in Amsterdam during
an enrolment period of one year will be screened at
baseline using the risk score and the ICD indications
according to the Consensus Statement. A flow chart
of the study design is presented in Fig. 2.
Assessment of risk
Patients are deemed to be at high risk for SCD when
they have at minimum a 3% annual risk of SCD ac-
cording to the risk score model. ICD implantation
may be considered in these patients. The control
group will consist of ACHD patients with a low risk
of SCD (<3% annually) according to the risk score.
The primary prevention indications from the afore-
mentioned Consensus Statement are listed in Tab. 1.
Patient selection
All patients included in this registry are adults
(≥18 years of age) who have been diagnosed with
a structural congenital heart defect.
Exclusion criteria are the following:
 secondary prevention ICD indication, i.e. sponta-
neous sustained ventricular tachycardia or fibrilla-
tion or survived cardiac arrest warranting ICD im-
plantation
 myocardial infarction in the previous three months
 high risk status or ICD indication according to the
Consensus Statement due to a transient cause, e.g.
tachycardiomyopathy or operable valvular dysfunc-
tion
 completion of follow-up is not possible
 a contra-indication for ICD implantation (including
NYHA IV heart failure)
Patients with congenital defects not represented in the
risk score will be excluded from the analysis compar-
ing patients with high and low risk scores, but may
still be screened by applying the Consensus Statement
indications.
Treatment of patients
As this is an observational study, follow-up examina-
tions and regular treatment of patients will be per-
formed by the patient’s own treating physician, with-
out intervention by the investigators. The decision on
whether to implant an ICD is at the treating physi-
cian’s discretion.
Follow-up
The initial follow-up period will be two years. After
these two years the endpoint of SCD or appropriate
ICD interventions in patients with an ICD will be ex-
amined. Hospital records will be inspected for SCD
events, sustained ventricular arrhythmia and appro-
priate ICD interventions.
Ethics approval
We obtained a waiver from the ethics committee at the
Academic Medical Center—University of Amsterdam,
as this observational study does not require approval
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from the ethics committee. The study was registered
at ClinicalTrials.gov (NCT03957824).
Endpoints and power calculation
The study is powered for the composite endpoint of
SCD or sustained ventricular arrhythmia at two years
of follow-up. Sustained ventricular arrhythmia is de-
fined according to international standards as any ven-
tricular fibrillation or ventricular tachycardia lasting
longer than 30seconds. In patients with an ICD, de-
vice programming will contain algorithms to prevent
unnecessary ICD therapy for self-terminating ventric-
ular arrhythmias [18].
The ratio of high-risk versus low-risk patients is es-
timated to be 1:10. We estimate that the two-year
risk of SCD or sustained ventricular arrhythmia for
low-risk patients is 0.4% and for high-risk patients is
6%. Considering an attrition of 10%, we calculated
that with 60 high-risk patients and 600 low-risk pa-
tients a high degree of confidence (>80% power) can
be provided to validate the risk score.
Secondary endpoints, in ACHD patients with an
ICD, are the rates of ICD-related complications and
inappropriate shocks.
Discussion
The prevention of SCD is a vital part of the care for
ACHD patients, but major difficulties in the indication
assessment for ICD implantation are yet to be over-
come. Current risk prediction methods, including the
current guidelines on ICD implantation in ACHD pa-
tients have shown to be of limited predictive value
[13].
Considering this, a novel risk score designed to
predict SCD in ACHD patients was developed, which
was internally validated using bootstrapping, and ex-
ternally validated in an independent registry cohort.
With PREVENTION-ACHD, we aim to validate this
risk score in a prospective study. In addition, the ICD
indications listed in the Expert Consensus Statement
on arrhythmias in ACHD patients will be assessed.
Risk score model
By means of the presented risk score model the pa-
tient’s individual risk for SCD can be assessed. The
risk score model concurs with risk factors previously
reported on specific cardiac defects and adds quanti-
tative data for other CHD lesions. Most studies seek-
ing risk factors for SCD in CHD have involved pa-
tients with surgically repaired tetralogy of Fallot (ToF)
and Mustard or Senning repair for transposition of the
great arteries (TGA). However, SCD also frequently oc-
curs in other CHD such as Eisenmenger syndrome,
left-sided lesions and septal defects, which are either
less prevalent or less well investigated. This risk score
model includes many types of cardiac lesions and may
be applied to a broad spectrum of patients.
Consensus Statement
The PACES/HRS Expert Consensus Statement on the
Recognition and Management of Arrhythmias in Adult
Congenital Heart Disease listed ICD recommenda-
tions for ACHD patients for the first time [11]. In
a retrospective analysis, the ICD recommendations
in the Consensus Statement failed to identify 60% of
SCD victims, ICD implantation was recommended in
17% of living controls, and the overall discriminative
ability was poor [13]. However, the Consensus State-
ment ICD recommendations have not yet been tested
in a prospective setting. PREVENTION-ACHD may
therefore provide more accurate results regarding the
discriminative ability of the ICD recommendations.
ICD implantation
Patients are classified into low-risk and high-risk
groups using the risk score to provide more distinctly
defined ICD indications and to reduce the number
of patients needed. We consider a≥3% annual risk of
SCD to be high, in part because of the young age of
ACHD patients who are at risk of SCD and the cumu-
lative rates that may be far higher than in the much
older population with acquired heart disease. More-
over, according to current ESC guidelines, patients
with hypertrophic cardiomyopathy are considered
candidates for primary prevention ICD implantation
when they have a 5-year SCD risk of 6% (class IIa).
Among other reasons, the high rate of complications
associated with ICD implantation in ACHD patients
made us reluctant to lower the cut-off rate for high-
risk patients, who may be considered for ICD implan-
tation, to similar numbers.
Limitations
Although the risk score model is derived from the
largest cohort of ACHD patients who were the vic-
tim of SCD, the number of cases providing data is
still limited [1]. The study was retrospective in nature,
and thus the inherent limitations of such a study de-
sign apply. However, it should be noted that to date,
no prospective studies on SCD in ACHD patients are
available.
Conclusion
Considering the expected rising incidence of SCD and
high complication rate associated with ICD implanta-
tion in ACHD patients, it is of paramount importance
to gather more robust evidence on the risk stratifica-
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tion for SCD and the indication for ICDs. PREVEN-
TION-ACHD is the first prospective study on SCD in
ACHD patients. A novel risk score predicting the risk
of SCD in ACHD patients and the ICD indications
listed in the 2014 Consensus Statement on arrhyth-
mias in adult congenital heart disease, are both aimed
to be validated with this study.
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